Darigabat
The article's lead section may need to be rewritten. (August 2023) |
Clinical data | |
---|---|
Other names | CVL-865; PF-06372865; PF-6372865 |
Routes of administration | Oral administration |
Drug class | GABAA receptor positive allosteric modulator |
Pharmacokinetic data | |
Metabolism | CYP3A4[1] |
Elimination half-life | 11 hours[1] |
Identifiers | |
| |
JSmol) | |
| |
|
Darigabat (developmental code names CVL-865, PF-06372865, PF-6372865) is a
chronic lower back pain, but development for these indications was discontinued.[2][3][4] It is taken via oral administration.[2]
Darigabat acts as a
In clinical trials conducted thus far,
memory impairment, mild cognitive impairment, balance impairment, and feeling abnormal.[3][6] It has been described as well-tolerated.[3][4]
Darigabat was originated by Pfizer and is under development by Cerevel Therapeutics and Pfizer.[2] As of January 2023, it is in phase 2 clinical trials for epilepsy and seizures, phase 1 trials for panic disorder, and preclinical development for anxiety disorders.[2][3] Development for back pain was discontinued due to lack of effectiveness in a phase 2 trial, while development for generalized anxiety disorder was discontinued due to business reasons as well as lack of effectiveness in a phase 2 trial.[3][4][2]